证券代码：600223 证券简称：福瑞达 编号：临 2025-024 鲁商福瑞达医药股份有限公司 关于取消监事会及修订《公司章程》和部分治理制度 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鲁商福瑞达医药股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召 开了第十二届董事会第六次会议，会议审议通过了《关于取消公司监事会及修订 <公司章程> 的议案》及《关于修订、制定公司部分治理制度的议案》，具体情况 如下： 一、取消监事会及修订《公司章程》和部分治理制度的原因及依据 为贯彻落实自 2024 年 7 月 1 日起实施的《中华人民共和国公司法》，进一 步提高公司规范化运作水平，根据《上市公司章程指引》《上市公司股东会规则》 《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等法律、法规和规范性文件要求，结合公司实际情况，拟取消监 事会，《公司法》规定的监事会职权由董事会审计委员会行使，公司《监事会议 事规则》相应废止，并对《公司章程》、《股东会议事规则》（原《 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-021 鲁商福瑞达医药股份有限公司 关于 2025 年第二季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将鲁商福瑞达医药股份有限公司（以下 简称"公司"）2025 年第二季度主要经营数据披露如下： 一、2025 年第二季度公司主要产品的产量、销量及收入实现情况 主要产品 产量（件） 销量（件） 营业收入（元） 护肤类 28,381,516.00 27,833,821.27 567,283,215.88 二、2025 年第二季度公司主要产品和原材料的价格变动情况 （一）主要产品价格变动情况 主要产 同比变动 环比变动 平均售价 平均售价 平均售价 品 比率（%） 比率（%） （元/件） （元/件） （元/件） 护肤类 19.88 19.78 20.38 2.52% 3.03% 护肤类产品 2025 年第二季度平均售价同比上升 2.5 ...

Group 1 - The core viewpoint of the report is that Shandong Provincial Commercial Group Financial Co., Ltd. has established a comprehensive internal control system and effectively manages risks, ensuring compliance with regulatory requirements [1][8] - The financial company was established with a registered capital of 2 billion RMB and has been operational since April 28, 2012, focusing on various financial services for its member units [1][2] - As of June 30, 2025, the financial company reported total assets of 843.59 million RMB, net assets of 248.34 million RMB, operating income of 11.75 million RMB, and net profit of 5.34 million RMB [6][7] Group 2 - The financial company has a governance structure that includes a board of directors, a supervisory board, and senior management, ensuring effective decision-making and oversight [2][4] - The company has implemented a risk management framework that includes regular audits and compliance checks, with no significant operational risks reported [6][8] - The company maintains a strong liquidity position, with deposits amounting to 150.47 million RMB, representing 51.05% of its cash balance, and a borrowing balance of 1.5 million RMB, accounting for 6.52% of total financing [7][8]

证券代码：600223 证券简称：福瑞达 编号：临 2025-023 鲁商福瑞达医药股份有限公司 关于聘任公司董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鲁商福瑞达医药股份有限公司（以下简称"公司"）于2025年8月20日召开 了第十二届董事会第六次会议，审议通过了《关于聘任公司董事会秘书的议案》， 经公司董事长提名，董事会提名委员会审查通过，董事会同意聘任窦茜茜女士为 公司董事会秘书（简历附后），任期与公司第十二届董事会一致。 窦茜茜女士已参加上海证券交易所董事会秘书任职培训并取得董事会秘书 任职培训证明，具备履行董事会秘书职责所必需的专业知识和工作经验，其任职 资格已经上海证券交易所备案无异议，符合《公司法》《上海证券交易所股票上 市规则》和《公司章程》等相关规定。 公司董事会秘书的联系方式如下： 电话：0531-66699999 传真：0531-66697128 电子邮箱：lsfrd600223@163.com 联系地址：山东省济南市高新区新泺大街888号 鲁商福瑞达医药股份有限公司董事会 附： ...

第三条 公司董事离职管理应遵循以下原则： （一）合法合规原则：严格遵守国家法律法规、监管规定及公司章程的要求； 第一章 总 则 第一条 为规范鲁商福瑞达医药股份有限公司（以下简称"公司"）董事离职 程 序，确保公司治理结构的稳定性和连续性，维护公司及股东的合法权益，公司根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《上市公司治理准则》《上海证券交易所股 票上市规则》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》 等法律法规、规范性文件、证券交易所业务规则及《鲁商福瑞达医药股份有限公司 章程》（以下简称"公司章程"）的有关规定，结合公司实际情况，制定本制度。 第二条 本制度适用于全体董事，包括非独立董事、独立董事以及职工董事离 职的情形。 （二）公开透明原则：及时、准确、完整地披露董事离职相关信息； （三）平稳过渡原则：确保董事离职不影响公司正常经营和治理结构的稳定性； （四）保护股东权益原则：维护公司及全体股东的合法权益。 第二章 离职情形与程序 第四条 公司董事离职包含任期届满未连任、主动辞职、被解除职务以及其他 导致董事实际离 ...

Core Points - The company has established a system to enhance information disclosure, ensuring timely, accurate, and complete information is provided to investors [1] - The system outlines the responsibilities of reporting personnel in the event of significant events that could impact investor decisions or stock prices [1][2] - The board secretary is responsible for external information disclosure, including periodic and temporary reports [2][5] Group 1: Reporting Obligations - Reporting personnel include company directors, senior management, and other relevant individuals who may have access to significant information [1][2] - The first responsibility for internal information reporting lies with the general manager and other senior management [2][5] - Shareholders holding more than 5% of the company's shares must report relevant information to the board secretary and office [2][5] Group 2: Scope of Major Information - Major information includes significant events authorized by the board, major operational incidents, and changes in laws or regulations that could impact the company [3][4] - Related party transactions exceeding specified thresholds must be reported, including transactions with individuals over 300,000 yuan and with entities over 3 million yuan [3][4] - Legal matters involving amounts over 5 million yuan must also be reported, along with any significant discrepancies in performance forecasts [4] Group 3: Reporting Procedures - Reporting personnel must report significant information to the board secretary and office immediately upon becoming aware of it [5][6] - Reports can be made in various forms, including written documents, phone calls, or meetings [5][6] - The board secretary is responsible for analyzing reported information and proposing disclosure plans as necessary [6][7] Group 4: Responsibilities and Compliance - The board office assists the board secretary in managing information disclosure and responding to inquiries from the public and investors [7] - Failure to report significant information in a timely manner will result in accountability for the responsible personnel [7][8] - The board of directors is responsible for interpreting the system and ensuring compliance with relevant laws and regulations [8]

Core Viewpoint - The document outlines the compensation management system for the board of directors and senior management of Lushang Furuida Pharmaceutical Co., Ltd, aiming to enhance governance and establish effective incentive and restraint mechanisms [1] Group 1: General Principles - The compensation system is designed to motivate directors and senior management by linking their pay to the company's long-term interests, scale, performance, and individual contributions [3][4] - The system emphasizes a balance between incentives and constraints, ensuring that compensation reflects both company performance and individual responsibilities [3] Group 2: Management Structure - The Compensation and Assessment Committee of the board is responsible for evaluating directors and senior management, setting assessment standards, and determining compensation policies [2][3] Group 3: Compensation and Assessment Management - Independent directors receive a fixed monthly allowance approved by the shareholders' meeting, while non-independent directors receive compensation based on their roles without additional allowances [2][3] - Senior management's compensation consists of a fixed salary and performance-based pay, with the latter determined by annual operational goals and individual performance [2][3] Group 4: Compensation Adjustment - The compensation system is adaptable to align with the company's development strategy and can be adjusted in response to significant changes in the operating environment [6] - Special rewards or penalties can be established for specific matters, subject to approval by the Compensation and Assessment Committee and the board [6] Group 5: Implementation and Compliance - The compensation management system will be executed in accordance with national laws and regulations, and the board is responsible for its interpretation and revision [7]

Group 1 - The company aims to enhance its governance mechanism and strengthen internal control by establishing a system for independent directors to supervise information disclosure [1] - Independent directors are required to diligently fulfill their responsibilities during the preparation and disclosure of the annual report, ensuring the report is true, accurate, and complete [1][2] - The management must provide a comprehensive report on the company's operational status and significant matters to independent directors at the end of each fiscal year [2] Group 2 - Independent directors are responsible for verifying the qualifications of the accounting firm and the registered accountants involved in the annual audit [2] - The company’s financial officer must submit the annual audit plan and relevant materials to independent directors before the audit begins [2] - There should be necessary communication between independent directors and the registered accountants, including a meeting to discuss audit findings before the board meeting [2][3] Group 3 - The company’s secretary is responsible for facilitating communication between independent directors and the management team during the annual report preparation [3] - This working system will take effect after being approved by the company's board of directors [3] - Any matters not covered by this system will be executed according to national laws and regulations, and the company’s articles of association [3]

公司依据法律法规的要求应当报送的，需要将报送的外部单位相关人员作为内 幕知情人备案。公司应将报送的相关信息作为内幕信息，并书面提醒报送的外部单 位及相关人员履行保密义务，不得泄漏依据法律法规报送的本公司未公开重大信息， 不得利用所获取的未公开重大信息买卖本公司证券或建议他人买卖本公司证券。 第七条 公司依照统计、税收征管等法律法规的规定向政府有关部门或其他外部 单位报送公司尚未公开的重大信息（含经营财务数据等）的，或公司在进行申请授 信、贷款、融资、商务谈判等事项时因特殊情况确实需要向对方提供公司的尚未公 开重大信息的，需将报送的外部单位相关人员作为内幕信息知情人登记在案备查。 第八条 公司对外信息报送人员应当书面告知外部单位及其工作人员，因保密不 当致使前述重大信息被泄露时，应立即通知公司，公司应在知悉后的第一时间向上 海证券交易所报告并公告。 第一条 为加强公司定期报告及重大事项在编制、审议和披露期间的外部信息使 用人管理，依据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券 交易所股票上市规则》等法律、法规、规范性文件及《鲁商福瑞达医药股份有限公 司章程》（以下简称"公司章程"）等有关规定，制 ...

第三条 资产减值准备计提范围包括金融资产、存货、合同资产和长期资产、 财务担保合同等。 第一章 总 则 第一条 为了进一步加强和规范鲁商福瑞达医药股份有限公司(以下简称"公 司")资产减值准备的确认、计量及核销管理,确保公司财务报表真实反映公司财务 状况和经营成果,有效防范和化解公司资产损失的风险,根据《中华人民共和国公司 法》 《中华人民共和国会计法》 《企业会计准则》等法律法规及其他相关规定的要求, 结合本公司的实际情况,制定本制度。 第二条 资产减值是指资产（包括单项资产和资产组，下同）的可回收金额低 于其账面价值,可回收金额为资产的公允价值减去处置费用后的净额与资产预计未 来现金流量的现值两者之间的较高者。 长期资产包括长期股权投资、以成本模式计量的投资性房地产、固定资产、在 建工程、使用权资产、无形资产、商誉以及其他长期资产等。 第四条 按照《企业会计准则》及公司会计政策规定，以公允价值计量且其变 动计入当期损益的金融资产及采用公允模式计量的投资性房地产，不属于本制度规 范范围。 第五条 本制度适用于公司总部、各级控股子公司以及纳入公司合并会计报表 范围内的其他主体。参股公司可参考执行。 第二章 资 ...